Roquette and Thermo Fisher Scientific have entered a distribution rights agreement for the Roquette portfolio of pharmaceutical ingredients in the United States and Canada to support the high growth potential in these markets. 

This collaboration brings together the chemical storage and supply chain solutions from Doe & Ingalls, a brand of Thermo Fisher Scientific, with the high quality pharmaceutical ingredients of Roquette to focus on helping customers achieve their product development and manufacturing goals, as well as anticipating future needs of the pharmaceutical industry. Roquette chose the Doe & Ingalls solution for their commitment to quality and customer service, and will utilize their experience and relationships within the industry to better serve customers globally. 

The full portfolio of Roquette pharmaceutical ingredients will be included in the distribution agreement, including the newly launched KLEPTOSE®  BioPharma HPB/HP grades hydroxypropyl β- cyclodextrins, recently acquired Microcrystalline Cellulose products and other market-leading excipients. 

Paul Smaltz, vice president, Global Business Unit, Pharmaceuticals, Roquette, said, “It was an easy decision to partner with Thermo Fisher Scientific. Their reputation within the industry is impressive and we are looking forward to growing our business together. They bring best-in-class logistics and Good Distribution Practice (GDP) Warehousing; in-depth technical knowledge of quality and regulatory needs within the industry; and a secure, transparent supply chain similar to our own.” 

Brian Parker, vice president & general manager, Production Chemicals, Thermo Fisher said, “Understanding customers’ needs to accelerate product into clinical manufacturing and ultimately supply patients, Thermo Fisher Scientific continues to build its product portfolio and service solutions. Collaborating with Roquette provides access to a global player with a breadth of innovative products for large molecule biologics and small molecule pharmaceuticals. Together we can better serve the exacting demands of the life sciences market.”